Spark hints at price for Luxturna

On its 3Q17 financial results call Tuesday, Spark Therapeutics Inc. (NASDAQ:ONCE) said its economic modeling for gene therapy Luxturna voretigene neparvovec valued the one-time treatment at over $1 million.

Luxturna is an adeno-associated virus (AAV) encoding the retinal pigment epithelium-specific protein 65kDA (RPE65) gene that

Read the full 440 word article

User Sign In